MedTrace Logo

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

NCT05176691 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-02-21

No results posted yet for this study

Summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL

Conditions

Interventions

DRUG

HMPL-760

Administered orally QD for 28-day cycles

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Vijay Jayaprakash, MBBS, PHD · Hutchison Medipharma Limited

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2022-11-16
Completion
2022-11-16
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Israel
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05176691 on ClinicalTrials.gov